Google
BIOA — BIOAGE LABS, INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
BIOA FAQ
What is BIOA's ROE?
BIOAGE LABS, INC reports a Return on Equity (ROE) of -23.72%.
What is BIOA's dividend yield?
BIOAGE LABS, INC offers a dividend yield of 0.00%.
What is BIOA's Deepscope Quality Score?
Deepscope rates BIOA's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BIOA?
Deepscope's AI Timing Score for BIOA is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BIOA belong to?
BIOAGE LABS, INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 16.54
Price
-0.66
(-3.84%)
Day Change
|
|
|---|
BIOA, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 16.54 |
| PBV / Sector |
2.02 / 2.74
|
| Earning Per Share | -1.95 |
| PE / Sector |
N/A / 23.29
|
| PEG or PE/Growth / Sector |
N/A / 0.11
|
| Average 1M Daily Value |
7.14 M
|
| Average 1W Daily Value |
8.49 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-03 09:11:28 |
| Symbol | BIOA |
| Name | BIOAGE LABS, INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 44.45 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 764.59 / 9,635.82 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5885 Hollis Street, EmeryVille, CA, United States, 94608
Phone: 510 806 1445
Website: https://bioagelabs.com
Employees: 60
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
